NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaicin Patch for the management of pain due to postherpetic neuralgia (PHN).… more →
GPCR Newscrimsoncanary wrote 1 year ago: NeurogesX have submitted a new drug application (NDA) with the U.S. FDAS for NGX-4010 Dermal Capsaic … more →
crimsoncanary wrote 1 year ago: NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based … more →
crimsoncanary wrote 1 year ago: NeurogesX has initiated a Phase 1 clinical trial of NGX-1998, a high-concentration, capsaicin-based … more →
crimsoncanary wrote 1 year ago: NeurogesX have published Phase 3 data of its lead capsaicin product NGX-4010 in Neurology. The trial … more →
crimsoncanary wrote 1 year ago: NeurogesX have submitted an IND for the liquid formulation of Capsaicin, NGX-1998 for the treatment … more →
crimsoncanary wrote 1 year ago: NeurogesX have submitted an IND for the liquid formulation of Capsaicin, NGX-1998 for the treatment … more →